ArticleEndocrine2016
Cardiovascular risk in adult hypopituitaric patients with growth hormone deficiency: is there a role for vitamin D?
Article in Endocrine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 59 citations in OpenAlex.
- Effects of Vitamin D Supplementation on IGF-1 and Calcitriol: A Randomized-Controlled Trial.Nutrients · 2017Trial
- Alcohol and Substance Use After Bariatric Surgery: Nutritional Risks and Clinical Implications in Long-Term Postoperative Care.Nutrients · 2026Review
- Vitamin D in pituitary driven osteopathies.Pituitary · 2024Review
- Decreased mannan-binding lectin level in adults with hypopituitarism; dependence on appropriate hormone replacement therapies.Frontiers in immunology · 2023Article
- Mediterranean Diet and Obesity-related Disorders: What is the Evidence?Current obesity reports · 2022Review
- Vitamin D: A Role Also in Long COVID-19?Nutrients · 2022Review
- Effects of adult growth hormone deficiency and replacement therapy on the cardiometabolic risk profile.Pituitary · 2022Review
- Observational
- Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors.Endocrine · 2022Article
- Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors?Journal of translational medicine · 2021Article
- Association of Trimethylamine N-Oxide (TMAO) with the Clinical Severity of Hidradenitis Suppurativa (Acne Inversa).Nutrients · 2021Observational
- Association of the Chronotype Score with Circulating Trimethylamine N-Oxide (TMAO) Concentrations.Nutrients · 2021Observational
- Is there any gender difference in epidemiology, clinical presentation and co-morbidities of non-functioning pituitary adenomas? A prospective survey of a National Referral Center and review of the literature.Journal of endocrinological investigation · 2021Article
- Phase angle and Mediterranean diet in patients with acne: Two easy tools for assessing the clinical severity of disease.Journal of translational medicine · 2021Observational
- Article
- Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors.Frontiers in endocrinology · 2021Observational
- Does Sars-Cov-2 threaten our dreams? Effect of quarantine on sleep quality and body mass index.Journal of translational medicine · 2020Article
- Observational
- Article
- Sex Differences of Vitamin D Status across BMI Classes: An Observational Prospective Cohort Study.Nutrients · 2019Observational
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypovitaminosis D represent an environmental risk factors for cardiovascular (CV) disease. To investigate the prevalence of hypovitaminosis D and the correlation between GH/IGF-I deficiency and hypovitaminosis D with CV risk in GH deficiency (GHD) patients. A link between these hormones has been shown. Forty-one hypopituitaric patients with GHD (22 males, age 18-84 years) and 41 controls were enrolled in the study. Anthropometric parameters, blood pressure, glucose and lipid profile, parathyroid hormone (PTH), 25(OH) vitamin D (vitamin D), metabolic syndrome (MS), GH peak after GHRH + ARG, IGF-I, and standard deviation score (SDS) of IGF-I (zIGF-I) were assessed. Vitamin D levels were lower in patients than in controls (21.3 ± 12.3 vs. 28.2 ± 9.4, p = 0.006). Deficiency was found in 51 % of patients versus 14.6 % of controls (p < 0.01), insufficiency in 26.8 versus 41.4 % (p = 0.269) and normal vitamin D levels in 21.9 versus 43.9 % (p = 0.060). The prevalence of dyslipidemia was 51.2 % in patients versus 12.1 % in controls (p < 0.001), type 2 diabetes mellitus (DM) was 7.3 versus 17 % (p = 0.292), hypertension was 44 versus 22 % (p = 0.060), and MS was 17 versus 14.6 % (p = 0.957). In patients, an association was found between the presence of hypovitaminosis D and the prevalence of dyslipidemia, hypertension and MS and between zIGF-I and the prevalence of hypertension. Hypovitaminosis D was the most powerful predictor of the prevalence of dyslipidemia and hypertension. GHD patients have an increased prevalence of hypovitaminosis D compared with controls. The presence of hypovitaminosis D was the most powerful predictor of the prevalence of dyslipidemia and hypertension in GHD patients, suggesting the involvement of both factors in the CV risk in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.